Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Liu, Na ^a   Cui, Rui Xue ^a   He, Qing Mei ^a   Huang, Bi Jun ^a   Sun, Ying ^a   Xie, Dan ^a   Zeng, Jing ^a   Wang, Hui Yun ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Biomarker; Dicer1; Nasopharyngeal carcinoma; Prognosis; Reduced expression

Indexed keywords

DICER; DICER11; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; DOWN REGULATION; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOPHARYNGITIS; SURVIVAL PREDICTION;

ADULT; AREA UNDER CURVE; DEAD-BOX RNA HELICASES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASE III; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872026528     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0360-3     Document Type: Article

References (39)

1. Curado MP, Edwards BK. Cancer incidence in five continents. Vol IX. IARC Scientific Pub. No. 160. Lyon: IARC; 2007.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Edge SB, Byrd DR. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
4. Au JS, Law CK, Foo W, Lau WH. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 2003;56:413-26.
5. Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73:1326-34.
6. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414-8.
7. Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest. 2007;25:315-21.
8. Lv X, Xiang YQ, Cao SM, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head Neck. 2011;33:780-5.
9. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363-6.
10. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005;579:5822-9.
11. Merritt WM, Lin YG, Han LY, et al. Dicer1, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359:2641-50.
12. Flavin RJ, Smyth PC, Finn SP, et al. Altered eIF6 and Dicer1 expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008;21:676-84.
13. Faggad A, Budczies J, Tchernitsa O, et al. Prognostic significance of Dicer1 expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol. 2010;220:382-91.
14. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer1 associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96:111-5.
15. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer1 in precursor lesions of lung adenocarcinoma. Cancer Res. 2007;67:2345-50.
16. Sugito N, Ishiguro H, Kuwabara Y, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res. 2006;12:7322-8.
17. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of Dicer1, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006;169:1812-20.
18. Grelier G, Voirin N, Ay AS, et al. Prognostic value of Dicer1 expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101:673-83.
19. Zighelboim I, Reinhart AJ, Gao F, et al. Dicer1 expression and outcomes in endometrioid endometrial adenocarcinoma. Cancer. 2011;117:1446-53.
20. Faber C, Horst D, Hlubek F, Kirchner T. Overexpression of Dicer1 predicts poor survival in colorectal cancer. Eur J Cancer. 2011;47:1414-9.
21. Ma J, Liu L, Tang L, et al. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007;13:1445-52.
22. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71:1356-64.
23. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038-44.
24. Li W, Yu CP, Xia JT, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393-9.
25. Liao WT, Wang X, Xu LH, et al. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer. 2009;115:1507-17.
26. Korbler T, Grskovic M, Dominis M. Antica M (2004) A simple method for RNA isolation from formalin-fixed and paraffin-embedded lymphatic tissues. Exp Mol Pathol. 2003;74:336-40.
27. Marshall OJ. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics. 2004;20:2471-2.
28. Yang HI, Yuen MF, Chan HLY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of the predictive score. Lancet Oncol. 2011;12:568-74.
29. Liu N, Chen NY, Cui RX, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13:633-41.
30. Sengupta S, Den Boon JA, Chen IH, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 2008;105:5874-8.
31. Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100:1002-11.
32. Cheng C, Fu X, Alves P, Gerstein M. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 2009;10:R90.
33. Guo X, Liao Q, Chen P, et al. The microRNA-processing enzymes: Drosha and Dicer1 can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138:49-56.
34. Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661-8.
35. Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004;101:300-6.
36. Han L, Zhang A, Zhou X, et al. Downregulation of Dicer1 enhances tumor cell proliferation and invasion. Int J Oncol. 2010;37:299-305.
37. Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting Dicer1 for metastasis control. Cell. 2010;141:1195-207.
38. Shao JY, Huang XM, Yu XJ, et al. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Anticancer Res. 2001;21:3021-9.
39. Cheng R, Lo K, Huang D, Tsao S. Loss of heterozygosity on chromosome 14 in primary nasopharyngeal carcinoma. Int J Oncol. 1997;10:1047-50.